Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01111955 · ClinicalTrials.gov registry record · Phase 2

Safety Study of BMS-823778 in Subjects With Type 2 Diabetes

A Phase 2 study, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 2
Development phase
62
Enrollment target

NCT01111955: Completed Phase 2 study, sponsored by Bristol-Myers Squibb.

NCT01111955 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 62 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01111955, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 2
Development phase
62 participants
Enrollment target

Study Summary

The purpose of this study is to assess the safety, tolerability and pharmacodynamic effects on fasting plasma glucose (FPG).

Interventions

  • DRUG Placebo
  • DRUG Metformin
  • DRUG BMS-823778

Trial Details

FieldValue
Enrollment Target 62 participants
Start Date 2010-07
Est. Completion 2011-01
Phase Phase 2
Bristol-Myers Squibb

1,025 total trials

What the finished NCT01111955 record still lists

NCT01111955 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower).

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT01111955 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01111955 about?

NCT01111955 is a clinical study titled "Safety Study of BMS-823778 in Subjects With Type 2 Diabetes". The purpose of this study is to assess the safety, tolerability and pharmacodynamic effects on fasting plasma glucose (FPG).

What is the current status of trial NCT01111955?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2010-07. Estimated completion is 2011-01.

What interventions are being tested in trial NCT01111955?

The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), BMS-823778 (DRUG).

Who is sponsoring clinical trial NCT01111955?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01111955's enrollment target sits among peer trials

62 1016th of 2000 higher than 975 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03231150 · 62 participants · NA

    Plantar Fasciitis Randomized Clinical Control Trial

  • NCT03458676 · 62 participants · NA

    Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies

  • NCT03596086 · 62 participants · Phase 1

    HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM

  • NCT03603405 · 62 participants · Phase 1

    HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01111955, the US trial registry maintained by the National Library of Medicine. NCT01111955 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.